Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis.
[lymphangioleiomyomatosis]
Lymphangioleiomyomatosis
(
LAM
)
is
a
rare
systemic
disease
of
young
women
arising
from
mutations
in
the
tuberous
sclerosis
complex
(
TSC
)
genes
,
TSC
1
or
TSC
2
.
This
disrupts
the
mammalian
target
of
rapamycin
(
mTOR
)
pathway
,
affecting
cellular
proliferation
and
growth
.
mTOR
inhibitors
are
a
promising
novel
therapy
in
LAM
.
The
mTOR
inhibitor
sirolimus
is
reported
to
produce
resolution
of
lymphatic
abnormalities
in
LAM
,
but
the
efficiacy
of
the
mTOR
inhibitor
everolimus
has
not
been
assessed
.
We
aimed
to
examine
the
efficacy
of
everolimus
on
lymphatic
abnormalities
in
LAM
.
O
pen
-label
treatment
of
five
patients
with
sporadic
LAM
(
sLAM
)
and
abdominopelvic
and
lung
involvement
at
the
outpatient
LAM
clinic
of
a
tertiary
city
teaching
hospital
.
Clinical
data
were
collected
during
treatment
of
the
women
and
included
regular
clinical
reviews
,
everolimus
levels
,
lung
function
and
computed
tomography
assessment
before
and
after
6
months
of
everolimus
treatment
.
Symptoms
and
level
of
resolution
of
lymphangioleiomyomas
.
A
ll
five
women
experienced
significant
shrinkage
or
complete
resolution
of
the
lymphangioleiomyomas
during
treatment
.
In
one
woman
,
cessation
of
everolimus
resulted
in
recurrence
of
symptoms
.
Adverse
events
were
compatible
with
the
known
side-effect
profile
of
everolimus
,
but
overall
the
drug
was
well
tolerated
.
This
is
the
first
report
to
suggest
that
everolimus
has
efficacy
in
the
treatment
of
lymphangioleiomyoma
and
chylous
ascites
in
sLAM
.
Diseases
Validation
Diseases presenting
"but the efficiacy of the mtor inhibitor everolimus has not been assessed"
symptom
lymphangioleiomyomatosis
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom